The total volume of finished medicine production in our country in Q1-Q2 2025 amounted to 475.9 billion rubles (at manufacturer shipment prices, including VAT). The growth rate compared to the same period in 2024, when calculated in Russian currency, reached 20.2%. According to information from the “Medicine production in Russia” database of the analytical company RNC Pharma, from January to June 2025, pharmaceutical companies located in Russia released approximately 1.88 billion packages of medicines into circulation, which is equivalent to 40.1 billion minimum dosage units (MDUs). Compared to Q1-Q2 2024, medicine production decreased by 7.2% in packages and by 1.8% in minimum units.

In June 2025, manufacturers shipped GLP worth 79 billion rubles, 12.1% more than in June 2024. At the same time, in real terms, over the past six months, only April saw positive dynamics, while the other months saw a decline in physical production volume. Thus, compared to June 2024, the growth rate in packages was -4.6%, and in May the decline was even more noticeable, at -12.5%. In total, pharmaceutical companies located in our country produced about 306.5 million packages of finished medicines or 6.5 billion MED (-2.3% compared to June 2024) in June 2025.

The decline in production in physical units is mainly due to OTC medicines. During the reporting period, their output decreased by more than 14%, while the volume of prescription medicines remained virtually unchanged (-0.09%).

The total number of corporations that shipped finished pharmaceutical products in the first half of 2025 was 402, which is 21 fewer than in January-June 2024. At the same time, the number of trademarks increased by 34 items compared to the first half of last year and reached 2,711. In recent years, there has been a steady trend toward expanding the range of medicines produced in Russia. The number of SKUs is also growing; from January to June of this year, the range of produced medicines included more than 9,000 product items (+192 items compared to Q1-Q2 2024).

The expansion of the manufacturers' portfolio is mainly due to generic medicines, but there are examples of products that are completely new to the Russian market. In Q1-Q2 2025, the hypoglycemic medicine Lusefi (INN luseogliflozin) from Servier and two brands with the INN tirzepatide from domestic manufacturers Geropharm and Promomed were released into circulation. Another example of intensive production growth by various companies is related to rivaroxaban medicines. By the end of January-June 2025, 18 analogues of Xarelto had been shipped to the market, with eight of them launched this year.

Among the top 20 over-the-counter brands leading in terms of natural production volume in January-June 2025, the brand Muravyinyi Spirt showed the highest growth, with volume increasing almost threefold over the year. Key contributors to this growth were the companies NIIMIS and Genel. The product is likely used as an alcohol substitute and replaces similar products. Also noteworthy is Cardiomagnyl from Nizhpharm (+22.6%). Rinostop from OTC Pharm (-46.6%) showed a decline in production among the top 20.

The best performance in the Rx category in the first two quarters of this year among the top 20 brands was demonstrated by the Sodium Chloride brand (+41.1%). The main contribution to the dynamics was made by products from Kraspharma and Mir. The most noticeable decline in production volumes was observed for unbranded azithromycin preparations (-49.5%).

Fig. Production volume of finished medicines in Russia (including medicines produced by foreign pharmaceutical companies at their own and contract sites) in 2020–2024 and Q1–Q2 2025 in physical terms (packages) and monetary terms (RUB, including VAT)